公開日期 | 標題 | 作者 | 來源出版物 | scopus | WOS | 全文 |
---|---|---|---|---|---|---|
2020 | Phase 1 study of capmatinib in MET-positive solid tumor patients: Dose escalation and expansion of selected cohorts | Bang Y.-J.; Su W.-C.; Schuler M.; Nam D.-H.; Lim W.T.; Bauer T.M.; Azaro A.; Poon R.T.P.; Hong D.; CHIA-CHI LIN ; Akimov M.; Ghebremariam S.; Zhao S.; Giovannini M.; Ma B. | Cancer Science | 43 | 35 | |
2015 | Phase 1 study of the investigational Aurora A kinase inhibitor alisertib (MLN8237) in East Asian cancer patients: Pharmacokinetics and recommended phase 2 dose | Venkatakrishnan K.; Kim T.M.; CHIA-CHI LIN ; Thye L.S.; Chng W.J.; Ma B.; Chen M.H.; Zhou X.; Liu H.; Kelly V.; Kim W.S. | Investigational New Drugs | 26 | 27 | |
2019 | Phase II APEC trial: The impact of primary tumor side on outcomes of first-line cetuximab plus FOLFOX or FOLFIRI in patients with RAS wild-type metastatic colorectal cancer | Price T.; Shen L.; Ma B.; Esser R.; Chen W.; Gibbs P.; Lim R.; ANN-LII CHENG | Asia-Pacific Journal of Clinical Oncology | 4 | 4 | |
2015 | Regorafenib plus best supportive care versus placebo plus best supportive care in Asian patients with previously treated metastatic colorectal cancer (CONCUR): A randomised, double-blind, placebo-controlled, phase 3 trial | Li J.; Qin S.; Xu R.; Yau T.C.C.; Ma B.; Pan H.; Xu J.; Bai Y.; Chi Y.; Wang L.; KUN-HUEI YEH ; Bi F.; Cheng Y.; Le A.T.; Lin J.-K.; Liu T.; Ma D.; Kappeler C.; Kalmus J.; Kim T.W. | The Lancet Oncology | 597 | 536 | |
2016 | The role of autoinducer-2 in aerobic granulation using alternating feed loadings strategy | Sun S.; Liu X.; Ma B.; Wan C.; Lee D.-J. | Bioresource Technology | 37 | 29 | |
2016 | Understanding of aerobic granulation enhanced by starvation in the perspective of quorum sensing | Liu X.; Sun S.; Ma B.; Zhang C.; Wan C.; Lee D.-J. | Applied Microbiology and Biotechnology | 47 | 42 |